Navigation Links
Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript
Date:6/6/2013

PHILADELPHIA and REHOVOT, Israel, June 6, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript reporting data validating the clinical utility of the Rosetta Cancer Origin Test (formerly miRview® mets2) to identify the tumor of origin in Cancer of Unknown or Uncertain Primary (CUP) has been accepted for publication in the peer-reviewed on-line journal Molecular Cancer. The article, titled "Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary," represents the seventh peer-reviewed publication relating to our CUP assays, and the fifth peer-reviewed publication relating to post market validation studies demonstrating the Cancer Origin Test's ability to identify tumor origin in CUP with 92% concordance, the highest level of accuracy of any similar study published to date.

The manuscript discusses the performance of the Cancer Origin Test, an assay utilizing 64 microRNAs to identify 42 tumor types, in formalin-fixed paraffin-embedded (FFPE) samples from 84 CUP patients The results showed concordance with the final diagnosis in 92% of patients; representing an improvement in agreement of 22 percentage points from presentation diagnosis to final diagnosis, which final diagnosis was  achieved after more precise clinical and pathological data was added to the data relied upon for the patient's initial assessment.

"MicroRNAs are particularly well-suited as biomarkers for identifying tumor origin as their expression levels and profile reflects tissue origin.  Importantly, microRNAs have been shown to be highly stable in tissue block
'/>"/>

SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
2. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
3. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
4. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
5. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
6. Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories
7. Rosetta Genomics Announces Presence at ASCO 2013
8. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
9. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
10. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
11. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Leading Regenerative Veterinary ... its allogeneic stem-cell product development program and changes ... the corporate strategic direction. , “I am extremely ... stem cell development program has been kicked into ... manufacturing facility and hiring of our new Director ...
(Date:4/24/2015)... PRINCETON, N.J. , April 24, 2015  Navitas Life ... Kumar as Head of Clinical and Regulatory Services. Shalabh ... having been a co-founder and CEO of Kinapse, as well ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
(Date:4/23/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology and medical device ... and the United States , today ... first quarter of 2015 after the New York Stock ... be Thursday morning, May 14, 2015 Shanghai time). The ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... by Novartis to evaluate safety and efficacy of Albuferon ... patients with genotypes 2 and 3 hepatitis C -ROCKVILLE, ... HGSI ) today announced that Novartis has ... evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) ...
... 12 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer ... today announced preliminary revenue,and earnings for the full ... Based upon preliminary data for the fourth quarter, ...
... Pharmaceuticals, a pioneer in the development of novel products ... disease, announced that Ted Hibben has joined the company ... from Coley Pharmaceutical Group, where he was most recently ... played a key role in the company,s $233 million ...
Cached Biology Technology:Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2Cequent Names Ted Hibben Chief Business Officer 2Cequent Names Ted Hibben Chief Business Officer 3
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... scientific conditions and measures, Johns Hopkins researchers have ... can induce mystical/spiritual experiences descriptively identical to spontaneous ... The resulting experiences apparently prompt positive changes in ... least. , The agent, a plant alkaloid ...
... on Long Island have identified which among several different kinds ... the widely prescribed antidepressant Prozac. This discovery might enable a ... side effects, to be developed. , The findings also lay ... how, when, and where new neurons are generated from stem ...
... for the first time that embryonic stem (ES) cells ... capacity to produce viable offspring. The research, published in ... avenues for future studies, including investigation of mechanisms involved ... for infertility. , Previous studies have shown that ES ...
Cached Biology News:Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 2Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 3Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 4Prozac's target revealed 2Sperm created in the laboratory from embryonic stem cells produce viable progeny 2
Yersinia pestis...
... The features we add to WinList come ... product every day. Features like automatic region ... the result of good suggestions, thoughtful conversations, ... the features you depend on are still ...
Insect Cell Lysis Buffer 50 ml...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Biology Products: